HomepageALMKT • EPA
add
Mauna Kea Technologies SA
Vorige slotkoers
€ 0,19
Dag-range
€ 0,18 - € 0,19
Jaar-range
€ 0,16 - € 0,53
Beurswaarde
12,00Â mln. EUR
Gem. volume
121,80K
Koers/winst
-
Dividendrendement
-
Primaire beurs
EPA
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(EUR) | jun 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 2,13Â mln. | -40,22% |
Bedrijfskosten | 3,51Â mln. | -5,78% |
Netto inkomsten | -2,34Â mln. | -267,42% |
Netto winstmarge | -109,77 | -380,03% |
Winst per aandeel | — | — |
EBITDA | -1,76Â mln. | -559,07% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
(EUR) | jun 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 3,82Â mln. | -39,56% |
Totale activa | 18,15Â mln. | -25,14% |
Totale passiva | 38,49Â mln. | -5,23% |
Totaal aandelenvermogen | -20,34 mln. | — |
Uitstaande aandelen | 64,62 mln. | — |
Koers-boekwaardeverhouding | -0,60 | — |
Rendement op activa | -25,45% | — |
Rendement op kapitaal | -56,78% | — |
Kasstroom
Nettomutatie in liquide middelen
(EUR) | jun 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -2,34Â mln. | -267,42% |
Operationele kasstroom | -1,90Â mln. | -233,29% |
Kasstroom uit beleggingen | 36,50K | 183,91% |
Kasstroom uit financiering | -226,50K | -218,90% |
Nettomutatie in liquide middelen | -2,09Â mln. | -232,96% |
Vrije kasstroom | -802,94K | -487,16% |
Over
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
Opgericht
2000
Website
Werknemers
65